Check out your Company Bowl for anonymous work chats.
Agios is proud to share our Q2 2023 Business Highlights and Financial Results!
We've closed our deal and are excited for the next chapter of our story!
We're re-imagining the other side of possible with a singular focus on genetically defined diseases -- and the right home and resources for our oncology portfolio.
We are excited to share about our partnership with Werk, and how we are thinking about flexibility as an organization! http://glassdoor.com/slink.htm?key=vMCma
We recently shared our Chief Executive Officer succession plan - click here to learn more!
Excellent Forbes piece on fighting cancer one patient at a time with precision medicines. At Agios, this is what motivates, inspires and drives us. http://glassdoor.com/slink.htm?key=vQDPI
Celgene and Agios received approval by the FDA for a new therapy for IDH2m relapsed/refractory acute myeloid leukemia http://glassdoor.com/slink.htm?key=vQ4K9
Business Insider reports on our approach to tackling diseases through dysregulated metabolism. Check it out: http://glassdoor.com/slink.htm?key=vQFx5
http://glassdoor.com/slink.htm?key=vQC82
http://glassdoor.com/slink.htm?key=vQaki
